David Amsellem
Stock Analyst at Piper Sandler
(4.41)
# 377
Out of 4,761 analysts
137
Total ratings
58.18%
Success rate
15.68%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Overweight | $310 → $329 | $303.01 | +8.58% | 2 | Feb 10, 2025 | |
| COLL Collegium Pharmaceutical | Maintains: Neutral | $37 → $36 | $29.13 | +23.58% | 7 | Feb 4, 2025 | |
| AMPH Amphastar Pharmaceuticals | Downgrades: Neutral | $66 → $36 | $31.28 | +15.09% | 7 | Feb 4, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $23 → $30 | $16.74 | +79.21% | 10 | Jan 17, 2025 | |
| ITCI Intra-Cellular Therapies | Downgrades: Neutral | $107 → $132 | $128.60 | +2.64% | 1 | Jan 14, 2025 | |
| AVDL Avadel Pharmaceuticals | Maintains: Overweight | $24 → $13 | $8.41 | +54.58% | 5 | Jan 10, 2025 | |
| SAGE Sage Therapeutics | Maintains: Overweight | $26 → $9 | $7.31 | +23.12% | 1 | Jan 2, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $160 | $120.69 | +32.57% | 9 | Dec 23, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $163 | $136.01 | +19.84% | 12 | Dec 12, 2024 | |
| VTRS Viatris | Reiterates: Neutral | $13 → $14 | $11.25 | +24.44% | 6 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $15 | $5.77 | +159.97% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $7.83 | +40.49% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $3.75 | -20.00% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $35.32 | +4.76% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $16 | $8.45 | +89.35% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $57.94 | +17.36% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $38 → $67 | $63.54 | +5.45% | 5 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $33.05 | +8.93% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $7.31 | -58.96% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $25.16 | +66.93% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $15.49 | +54.94% | 5 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.01 | +232.23% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.82 | +1,057.02% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $137.75 | -17.97% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $144 → $12 | $4.97 | +141.45% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $34.56 | +21.53% | 3 | Oct 16, 2023 |
Amgen
Feb 10, 2025
Maintains: Overweight
Price Target: $310 → $329
Current: $303.01
Upside: +8.58%
Collegium Pharmaceutical
Feb 4, 2025
Maintains: Neutral
Price Target: $37 → $36
Current: $29.13
Upside: +23.58%
Amphastar Pharmaceuticals
Feb 4, 2025
Downgrades: Neutral
Price Target: $66 → $36
Current: $31.28
Upside: +15.09%
Teva Pharmaceutical Industries
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $16.74
Upside: +79.21%
Intra-Cellular Therapies
Jan 14, 2025
Downgrades: Neutral
Price Target: $107 → $132
Current: $128.60
Upside: +2.64%
Avadel Pharmaceuticals
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $8.41
Upside: +54.58%
Sage Therapeutics
Jan 2, 2025
Maintains: Overweight
Price Target: $26 → $9
Current: $7.31
Upside: +23.12%
Neurocrine Biosciences
Dec 23, 2024
Reiterates: Overweight
Price Target: $160
Current: $120.69
Upside: +32.57%
Jazz Pharmaceuticals
Dec 12, 2024
Reiterates: Overweight
Price Target: $163
Current: $136.01
Upside: +19.84%
Viatris
Dec 6, 2024
Reiterates: Neutral
Price Target: $13 → $14
Current: $11.25
Upside: +24.44%
Nov 13, 2024
Maintains: Overweight
Price Target: $45 → $15
Current: $5.77
Upside: +159.97%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $7.83
Upside: +40.49%
Nov 11, 2024
Downgrades: Neutral
Price Target: $3
Current: $3.75
Upside: -20.00%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $35.32
Upside: +4.76%
Oct 25, 2024
Reiterates: Overweight
Price Target: $15 → $16
Current: $8.45
Upside: +89.35%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $57.94
Upside: +17.36%
Sep 18, 2024
Maintains: Overweight
Price Target: $38 → $67
Current: $63.54
Upside: +5.45%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $33.05
Upside: +8.93%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $7.31
Upside: -58.96%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $25.16
Upside: +66.93%
Apr 29, 2024
Maintains: Overweight
Price Target: $22 → $24
Current: $15.49
Upside: +54.94%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.01
Upside: +232.23%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.82
Upside: +1,057.02%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $137.75
Upside: -17.97%
Nov 14, 2023
Downgrades: Neutral
Price Target: $144 → $12
Current: $4.97
Upside: +141.45%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $34.56
Upside: +21.53%